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a b s t r a c t
Background: The live, temperature-attenuated vaccine strain 1B of Chlamydia abortus, the aetiological
agent of ovine enzootic abortion (OEA), has been implicated in cases of vaccine breakdown. The aim of
this study was to understand the nature of this attenuation through sequencing of the vaccine parent
strain (AB7) and the derived mutant strains 1B and 1H, as well as to clarify the role of the vaccine strain
in causing disease through comparative whole genome analysis.
Methods: Whole genome sequencing was performed on: vaccine parent strain AB7; N-methyl-N0-nitro-
N-nitrosoguanidine (NTG)-induced temperature attenuated mutant strain 1B grown from the commer-
cial live vaccines Cevac Chlamydia and Enzovax; strain 1H a reverted NTG mutant; and 5 strains isolated
from cases of OEA originating from animals from the original vaccine safety trial (2 strains) or from
vaccinated ewes or ewes exposed to vaccinated animals (3 strains).
Results: We confirmed that AB7 is in a different lineage from the reference strain S26/3. The genome of
vaccine strain 1B contains ten single nucleotide polymorphisms (SNPs) created by the NTG treatment,
which are identical to those found in strain 1H. The strains from OEA cases also cluster phylogenetically
very tightly with these vaccine strains.
Conclusions: The results show that C. abortus vaccine strain 1B has an identical genome sequence to the
non-attenuated ‘‘reverted mutant” strain 1H. Thus, the protection of the 1B vaccine is unlikely to be due
to the NTG induced SNPs and is more likely caused by the administration of high doses of C. abortus
elementary bodies that stimulate protective immunity. Vaccine-identical strains were also isolated from
cases of disease, as well as strains which had acquired 1–3 SNPs, including an animal that had not been
vaccinated with either of the commercial live OEA vaccines, indicating that the 1B vaccine strain may be
circulating and causing disease.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
The Gram-negative, obligate intracellular bacterium Chlamydia
abortus (formerly Chlamydophila abortus) is one of the most
common causes of infectious abortion in small ruminants world-
wide [1,2]. Vaccines targeting the disease (known as ovine enzootic
abortion (OEA) or enzootic abortion of ewes (EAE)) have been
developed commercially [3], including two live attenuated
vaccines (Enzovax, MSD Animal Health; Cevac Chlamydia, Ceva
Animal Health Ltd), which are based on an attenuated mutant
strain of C. abortus (strain 1B) that was generated following N-m
ethyl-N0-nitro-N-nitrosoguanidine (NTG) mutagenesis of a
wild-type field strain (AB7) isolated from an aborted lamb [4].
Mutagenesis of AB7 produced two temperature-sensitive mutant
strains, 1B and 1H, that were characterized as having a reduced
growth rate at 39.5 C and increased thermolability at 51 C
resulting in a reduced infectivity and ability to induce death in
utero when compared to parent strain AB7 [5,6]. Strain 1H was
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subsequently found to be unstable and reverted to virulence but 1B
was stable after multiple passages in vitro and in vivo [7] and could
protect against C. abortus infection, reinfection and shedding [6,8].
To understand the basis of the attenuation, strain 1B, the
reverted mutant strain 1H and parent strain AB7 were sequenced
using NimbleGen technology [9]. Comparative genome analysis
of AB7 with the C. abortus reference sequence strain S26/3 identi-
fied 591 single-nucleotide polymorphisms (SNPs), while only 22
SNPs were identified between AB7 and 1B, 20 of which were also
present in 1H. Analysis of the 22 mutations led to the conclusion
that the temperature-sensitive phenotype of 1B resulted from
disrupted metabolic activity, altered pyruvate kinase expression
and/or the alteration of the function of membrane proteins [9].
In order to further understand the nature of the attenuation
leading to the temperature-sensitive phenotype of 1B we have per-
formed full genome resequencing of the two mutant strains 1B and
1H and parent strain AB7 using Illumina technology. Vaccine strain
1B has also been uniquely detected in the placentas of vaccinated
sheep that have aborted as a result of OEA in comparable numbers
to those found in wild-type infections, implicating the vaccine-
derived strain as a probable cause of disease in some vaccinated
animals [10–13]. Therefore, we additionally aimed to clarify this
likely causal role of the vaccine strain in cases of OEA in vaccinated
animals through whole genome comparative analysis.
2. Material and methods
2.1. Chlamydia abortus strains, propagation and preparation of
genomic DNA
Nine C. abortus strains were selected for genome sequencing:
reverted NTG-mutant strain 1H; virulent field strain AB7, isolated
in France from an aborted lamb [4], from which 1B and 1H were
derived [5]; two different preparations of the NTG-mutant strain
1B prepared from the commercial vaccines Enzovax (MSD Animal
Health, UK; referred to as 1B-Enzovax) and Cevac Chlamydia
(Ceva Animal Heath Ltd, UK; referred to as 1B-Cevac); two strains
(6012 and 6181) isolated in Scotland in 1994 from vaccinated ewes
that subsequently aborted during the original Enzovax field safety
trial [11]; and three field strains isolated from the placentas of vac-
cinated ewes that aborted (strain 10DC0084 from Germany [14])
and 11-669_5380/2 from France [15]) and from the vaginal swab
of an unvaccinated aborted ewe that had extensive contact with
an OEA vaccinated herd (strain AB15 from France [10]).
Strains were propagated and infected cells harvested to purify
chlamydial elementary bodies for genomic DNA extraction, as
described previously [16] or by using a Wizard DNA extraction
kit (Promega, UK).
2.2. Genome sequencing, mapping, assembly and analysis
C. abortus AB7, 1B-Cevac, 1B-Enzovax, 1H, 11-669_5380/2,
10DC0084, AB15, 6012 and 6181 genomes were sequenced using
the Illumina HiSeq platform with 75-bp paired end reads resulting
in a mean genome coverage of 135, 300, 14, 208, 40, 273, 169, 10
and 10x, respectively, after mapping against reference strain
S26/3 [16] using SMALT (http://www.sanger.ac.uk/science/tools/
smalt-0), with a minimum identity threshold for mapping of 80%.
For 1B-Cevac, reads were assembled using Velvet v1.0.12 [17] with
manual improvement to produce a single contig. The genomes of
the other 8 strains were derived through mapping of sequence
reads against the 1B-Cevac and S26/3 [16,18] reference genomes
using SMALT. SNPs were called using GATK with indel realignment
and were manually checked against mapped reads with even the
lower coverage samples providing sufficient data for confident
base calls.
Annotation was transferred from strain S26/3 [16] to the
genomes of AB7 and 1B using AnnotateBacteria [https://github.
com/sanger-pathogens/Bio-AutomatedAnnotation/blob/master/lib/
Bio/AutomatedAnnotation/CommandLine/AnnotateBacteria.pm], as
previously described [19], and manually curated using Artemis
[20]. Comparative genome analysis was performed using the
Artemis Comparison Tool (ACT) [21]. The AB7, 1B and 1H genomes
were manually curated for the presence of pseudogenes, which
were defined as having one or more mutations (frameshift,
premature stop codon) that would ablate expression.
2.3. PCR SNP analysis
The 22 SNP differences between strains AB7, 1B and 1H that
were identified previously [9], as well as new SNPs identified in
this study, were additionally verified by PCR in all 3 strains. PCR
was performed in 50 ml reactions containing 1  Biomix (Bioline,
London, UK), 10 pmol each primer (Table S1) and 50 ng genomic
DNA. PCR cycle conditions comprised: denaturation at 94 C for
2 min; 35 cycles of denaturation at 94 C for 15 s, primer annealing
at 52–60 C (depending on primer Tm) for 15 s and extension at
72 C for 15 s; and a final extension step at 72 C for 2 min. PCR
products were purified using a QIAquick PCR Purification Kit
(QIAGEN Ltd., Manchester, UK), according to manufacturer’s
instructions and sequenced by Eurofins Genomics (Ebersberg,
Germany). Amplicon sequences were aligned against the S26/3,
AB7 and 1B genome sequences using MegAlign Pro (DNASTAR
Lasergene suite; https://www.dnastar.com/t-allproducts.aspx) to
verify the presence or absence of SNPs.
2.4. Nucleotide sequence accession numbers
Genomesequences of AB7, 1B-Cevac and1Hhave beendeposited
in EMBL under accession numbers LN554882, LN589721 and
LN554883, respectively. Read data for AB7, 1B-Cevac, 1B-Enzovax,
1H, 6012, 6181, 10DC0084, 11-669_5380/2 and AB15 have been
deposited in the European Nucleotide Archive (ENA, http://www.
ebi.ac.uk/ena/) under accessions ERS200120, ERS200134,
ERS067056, ERS200121, ERS200136, ERS200137, ERS067060,
ERS200127 and ERS200131, respectively.
3. Results
3.1. Comparative analysis of C. abortus vaccine parent strain AB7 to
strain S26/3
The genome of strain AB7 was determined to be 1,144,467 bp
with a G+C content of 39.86%, containing 960 CDSs, a single rRNA
operon and 38 tRNA genes. After careful read pair analysis, pmp12G
was found to be identical to pmp17G, as in S26/3 [16]. AB7 was
found to have 604 SNPs compared to S26/3, affecting 371 CDSs
and 75 predicted intergenic regions, plus 59 indels (Table S1). SNPs
and indels were distributed evenly throughout the AB7 genome
(Fig. 1; Table S2). A total of 283 non-synonymous mutations plus
ten indels, affecting 237 CDSs were identified. Twenty-one of the
30 pseudogenes present in S26/3 [16] were found to have SNPs
and indels in AB7 (Table S2), which either did not affect their
pseudogene status (n = 14) or produced intact CDSs (n = 7).
Overall 26 pseudogenes were identified in AB7, of which three
were unique in comparison with S26/3 (Table S3). These three
unique pseudogene differences resulted from single frame-shift
mutations present in the homopolymeric nucleotide tracts of
pmp13G (AB7_3131), a hypothetical protein gene (AB7_6101) and
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a conserved hypothetical membrane protein gene (AB7_6181), and
thus possibly subject to phase variable expression [16]. Of the
remaining 23 pseudogenes that are present in both AB7 and
S26/3, three also have single frame-shift mutations in homopoly-
meric nucleotide tracts (CAB279/AB7_3121, CAB383A/AB7_4301
and CAB516/AB7_5781), while the others have single or multiple
frame-shifts/premature stop codons (n = 16) and/or lack a transla-
tional start site (n = 4) (Table S3).
3.2. Comparative analysis of the NTG-derived mutants 1B and 1H with
their parent strain AB7
The genomes of 1B-Cevac and 1B-Enzovax were determined to
be identical. We identified ten SNP differences between the gen-
omes of 1B and AB7, which included nine of the 22 previously
identified SNPs [9], and an additional SNP (within CAB843/
AB7_9301/Cevac_9301) not previously identified (Table 1). Of the
other 13 previously identified SNPs [9], we found 11 to be also pre-
sent in AB7 and thus identical between AB7 and 1B, while the
remaining two were found to be identical in S26/3, AB7 and 1B
(SNPs in CAB281/AB7_3131/Cevac_3131 and CAB469/AB7_5251/
Cevac_5251) and thus not SNPs in any of the studied genomes
(Table 1). Due to the more advanced technology and high coverage
used in this study, in conjunction with the thorough manual con-
firmation of SNPs (Fig. S1) and PCR analysis of all SNP differences
between 1B, 1H and AB7 (Table S1), we have very high confidence
in the genomic data presented.
The ten confirmed SNPs differentiating 1B from AB7 are found in
genes encoding a sigma-54-dependent response regulator
(Cevac_1701/CAB096), export protein (Cevac_1951/CAB175), serine
hydroxymethyltransferase (Cevac_2471/CAB220), Pmp15G
(Cevac_3171/CAB283), lipoprotein (Cevac_3441/CAB308),
methionyl-tRNA synthetase (Cevac_6911/CAB622), phosphate
starvation-inducible protein (Cevac_7071/CAB636), valyl-tRNA
synthetase (Cevac_7201/CAB648), alanyl-tRNA synthetase
(Cevac_9291/CAB842) and a putative transcription-repair coupling
factor (Cevac_9301/CAB843; the newly identified SNP) (Table 1).
All these mutations, with the exception of the SNP within
Cevac_9291/CAB842, are non-synonymous. The SNP in pmp15G
(Cevac_3171/CAB283) results in a premature stop codon and trun-
cation of the protein product. No indels were identified. All SNPs
are annotated in the deposited genome of 1B-Cevac. The two SNPs
that previously differentiated the non-attenuated reverted mutant
strain 1H from 1B (CAB281 and CAB469 in [9]; Cevac_3131 and
Cevac_5251 in Table 1 in this study) were not present, revealing
the genomes of 1H and 1B to be identical.
3.3. Genome sequencing of strains isolated from cases of OEA
The strains 6012 and 6181, isolated from the aborted placentas
of sheep vaccinated with Enzovax during the original vaccine
safety trials, were found to have identical genome sequences to
strain 1B (Fig. 2). Field strains 11_669_5380/2 and 10DC0084, iso-
lated from animals vaccinated with 1B-Enzovax or 1B-Cevac and
aborted as a result of OEA, were found to have two or three SNPs
in addition to the ten unique SNPs, therefore being clearly des-
cended from the NTG-derived strains (Fig. 2, Table 2). The two
SNPs in 11_669_5380/2 consist of a G? A SNP in the intergenic
region upstream of Cevac_1941 and a T? G SNP resulting in a
Cys? Gly substitution in a hypothetical protein (Cevac_6631).
The three additional SNPs in 10DC0084 consist of an A? T SNP
resulting in a non-synonymous substitution in a CDS encoding a
phosphate permease (Cevac_0681), a C? T SNP resulting in an
Ala? Val substitution in a hypothetical protein (Cevac_1301)
and a C? T SNP resulting in a synonymous substitution in a 1,4
alpha-glucan branching enzyme (Cevac_2911). Strain AB15, from
an unvaccinated animal that had extensive contact with a flock
vaccinated with the live 1B C. abortus vaccine strain, was also
found to cluster with the 1B vaccine strain, with one further unique
T? G SNP resulting in a Ser? Ala substitution in a putative alco-
hol phosphatidyltransferase (Cevac_1381).
4. Discussion
Comparative genomic analysis of the C. abortus vaccine parent
strain AB7 with UK reference strain S26/3 revealed very similar
results to the Burall et al. [9] study, with an additional 13 SNPs
affecting an additional eight CDSs in AB7. We did note a discrep-
ancy in the number of indels present, with an additional 51 (59
in total) identified in our study. The majority of these indels (n =
49) are present in non-protein coding intergenic regions, while
those present in CDSs (n = 10) are predicted to have little effect
on protein coding, either adding a few additional amino acids or
affecting the last few C-terminal amino acids. Burall et al. [9] noted
that three of the 14 genes they observed with more than two
protein-altering non-synonymous mutations were pmp genes, con-
sistent with their characterization as a highly polymorphic gene
family. In our study we identified 15 genes with three or more
non-synonymous mutations, of which four are pmp genes
(CAB200/AB7_2251, CAB270/AB7_3031, CAB273/AB7_3051 and
CAB776/AB7_8571), and two of these (CAB270/AB7_3031 and
CAB273/AB7_3051) are pseudogenes with additional frame-shifts
C. abortus
strain AB7
1,144,467 bp
Fig. 1. Circular representation and genome comparison of C. abortus strains AB7,
S26/3 and 1B/1H. The outer scale shows the size in base pairs. From the outside in:
tracks 1 and 2 show the position of genes transcribed in a clockwise and
anticlockwise direction, respectively. CDSs in tracks 1 and 2 are colour coded
according to the function of their gene products: membrane or surface structures
(dark green); central or intermediary metabolism (yellow); degradation of macro-
molecules (cyan); information transfer/cell division (red); degradation of small
molecules (purple); regulators (pale blue); pathogenicity or adaptation (dark blue);
energy metabolism (black); conserved hypothetical (orange); unknown (pale
green); pseudogenes (brown). Track 3, SNP differences between AB7 and S26/3.
Track 4, pseudogene similarities and differences between AB7 and S26/3: shared
pseudogenes (brown); S26/3-specific pseudogenes (dark green); AB7-specific
pseudogenes (red). Track 5, SNPs present in 1B relative to AB7: Burall et al. [9]
SNPs confirmed (magenta) or not identified (dark blue) in this study; Burall et al. [9]
SNPs in 1B relative to 1H which were not found in this study (cyan); unique SNP
found in this study (dark green). Track 6, G + C content plot (in a 10 kb window);
track 7, GC skew plot ([G  C]/[G + C] (in a 10 kb window). (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of
this article.)
D. Longbottom et al. / Vaccine 36 (2018) 3593–3598 3595
in homopolymeric tracts, suggesting they are possibly subject to
phase-variable expression. Again, this is consistent with them
being a highly polymorphic gene family and having a role in dis-
ease pathogenesis [16].
Comparison of the parent (AB7) and mutant (1B and 1H) vac-
cine strains, however, revealed notable differences with the Burall
et al. [9] study, where 22 SNP differences were identified between
the mutant strains and AB7 using Nimblegen resequencing arrays.
Our study, using a more accurate high-throughput sequencing
approach and genome coverage of 300, has identified only ten,
including eight of the originally identified non-synonymous muta-
tions plus an additional previously unidentified non-synonymous
mutation in a transcription-repair coupling factor protein
(Cevac_9301), as well as a synonymous mutation in an alanyl-
tRNA synthetase (Cevac_9291). Of the 13 mutations originally
identified [9] that were found to be absent in our study by
sequencing and PCR analysis, 12 were synonymous (n = 9) or in
intergenic regions (n = 3), while the thirteenth was a non-
synonymous mutation in pmp9G (Cevac_3051), which although
ablating a premature stop codon in the corresponding protein pro-
duct did not affect the pseudogene status of this gene. Intriguingly,
the two previously identified differences between the vaccine
mutant strain 1B and reverted mutant strain 1H [9] in pmp13G
(Cevac_3131/ CAB281) and recR (Cevac_5251/ CAB469) were not
present in our study, with the same nucleotides present in all four
strains (S26/3, AB7, 1H and 1B). This agrees with a previous study
that had already revealed the absence of one of these SNPs
(Cevac_3131/CAB281) [11]. The fact that 1B and 1H are completely
identical raises important questions concerning the nature of the
temperature-sensitive phenotype of the 1B strain. Indeed, Burall
et al. [9] made little comment or discussion with regard to the dif-
ferences between 1B and reverted mutant strain 1H, other than
suggesting that 1B is derived from 1H and that the two identified
silent mutations could affect a regulatory sequence and protein
Table 1
SNPs identified in C. abortus mutant strains 1B/1H relative to vaccine parent strain AB7 and UK reference strain S26/3.
Genomic positiona CDSb Protein product SNPs: Burall et al.
(2009)
SNPs: this study
S26/3 AB7 & 1B S26/3 AB7 & 1B S26/3 & AB7 1H 1B S26/3 AB7 1H & 1B Mutation
classc
Amino acid
changed
110655 110648 096 1071 putative 50S ribosomal protein l2 C A A C A A – –
147575 147568 139 1531 putative lipoprotein C T T C T T – –
164031 164286 153 1701 putative sigma-54 dependent response
regulator
C T T C C T Non E? K
189518 189504 175 1951 putative protein export protein G A A G G A Non V? I
205074 205059 n/ae n/ae n/ae C T T C T T – –
241667 241651 220 2471 putative serine hydroxymethyltransferase G A A G G A Non D? N
247417 247401 227 2531 conserved hypothetical protein G A A G A A – –
312724 312707 273 3051 Pmp9G (pseudogene) C A A C A A – –
323028 323012 281 3131 Pmp13G G G A G G G – –
328034 328018 283 3171 pmp15G C T T C C T Non W? *f
335181 335165 n/ae n/ae n/ae T C C T C C – –
358346 358327 308 3441 putative lipoprotein C T T C C T Non E? K
429384 429384 373 4181 putative inner membrane protein T C C T C C – –
453290 453312 394 4431 putative glycosyl hydrolase A C C A C C – –
542479 542469 469 5251 recR A A G A A A – –
716144 716136 622 6911 methionyl-tRNA synthetase C T T C C T Non E? K
731338 731329 636 7071 putative phosphate starvation-inducible
protein
C T T C C T Non G? D
744408 744400 n/ae n/ae n/ae C T T C T T – –
754284 754282 648 7201 valyl-tRNA synthetase G A A G G A Non P? S
891683 891735 772 8531 putative TMH-family membrane protein A T T A T T – –
974264 974300 842 9291 putative alanyl-tRNA synthetase G A A G G A Syn –
976325 976361 843 9301 putative transcription-repair coupling
factor
G G G G G A Non G? S
1036695 1036784 887 9791 trigger factor A C C A C C – –
a Genomic position in the S26/3 (CR848038), AB7 (LN554882) and 1B-Cevac (LN589721) genomes.
b CDS, coding sequence. Gene number of coding sequence containing the specific SNP in S26/3 (designated CABxxx), AB7 (AB7_xxxx) and 1B-Cevac (CEVAC_xxxx).
c Non-synonymous (Non) or synonymous (Syn) codon change resulting from SNPs or intergenic (Int) location of SNPs in 1H and 1B relative to AB7.
d Amino acid change resulting from SNPs in AB7, 1H and 1B relative to S26/3 or 1H and 1B relative to S26/3 and AB7.
e n/a, not applicable as in intergenic region.
f *, stop codon.
Fig. 2. Phylogenetic tree showing the relationship of strainswithin the vaccine strain
clade using reference strain S26/3 as the outgroup. For clarity, the distance to S26/3 is
not representative (as indicated by the dashed lines) and represents 604 SNPs from
AB7. Ten SNPs separate AB7 from 1B-Cevac/1B-Enzovax with AB15, 11_669_5380/2
and 10DC0084 containing an additional 1, 2 and 3 SNPs, respectively.
3596 D. Longbottom et al. / Vaccine 36 (2018) 3593–3598
folding through differences in codon usage; however, as we now
know the two strains to be genomically identical these possibilities
are no longer relevant. Irrespective of this 1H versus 1B issue, the
authors did go on to suggest that the attenuated phenotype of 1B
results from multiple mutations affecting the Pho regulon, altered
pyruvate kinase activity (resulting from a mutation affecting pro-
moter function for CAB645), and membrane proteins Pmp15G
and a lipoprotein. While these mutations have been validated in
our study, with the exception of the mutation affecting CAB645,
we think that there is a more likely explanation as to why the live
vaccines protect sheep from infection, but yet appear to have the
capacity to cause infection.
In previous studies we have provided molecular (PCR-RFLP and
quantitative PCR) evidence suggesting that the commercial live
vaccines have the capacity to cause abortion in some vaccinated
animals [11,13,22]. In this study we provide genomic evidence that
such strains isolated from cases of OEA contain the same SNPs as
those present in the 1B vaccinal strain, based on isolates collected
from vaccinated aborted ewes during the original vaccine safety
trials conducted in the UK in the 1990s, or prepared very recently
from the two purchased commercial vaccines. This suggests that
the vaccine strain has remained unchanged over the last 20 years
of use at least and so there are no additional mutations that could
be linked to an altered propensity to cause disease. This also pro-
vides strong evidence that the strains present in these vaccinated
and aborted animals are indeed the vaccinal strain. If this is the
case then this means, as previously suggested [22], that this live
vaccine has likely always had the capacity to cause disease, but
that it is only recently since the development of molecular DIVA
tools that differentiate vaccinal from wild type strains [10–11] that
this has come to light. Our study has also identified a field strain
(AB15) from an animal that was reported as not being vaccinated
but in contact with animals that had been vaccinated as being
almost identical to strain 1B. This is first experimental evidence
suggesting the transmission of the vaccinal strain from animal to
animal. However, this interpretation is dependent on the accuracy
of the vaccine records for the farm in question and cannot discount
possible mistakes in record keeping. This finding is supported by
the additional SNPs found in strains 11-669_5380/2 and
10DC0084, suggesting that the vaccine strain may even be circulat-
ing in flocks and mutating over time. However, further evidence is
required to confirm this possibility.
If the vaccine strain can cause disease it does raise questions as to
how and why this is seen in some animals and not others. The live
vaccine strain is thought to elicit protectionwithout causing disease
due to attenuation resulting in absence of growth of the pathogen
within the animal at 39.5 C (the body temperature of sheep). How-
ever, our study has failed to identify the genetic basis of such a
temperature-sensitive phenotype, suggesting that the pathogen
does have the capacity to multiply within the animal and infect
the placenta causing disease. However, an important observation
was noted in a study we published in 2013 [22] that may explain
why we do not observe disease in all animals. In this study, we
observed that inoculation of ewes prior to pregnancy with low
(5  103 IFU) and medium (5  105 IFU) doses of C. abortus resulted
in infectionand abortion typical ofwhat is observedwith thedisease
in the field, while inoculation with a high dose (5  107 IFU) stimu-
lated a protective immune response [22]. As the commercial vacci-
nes are administered at a dosage ranging 105–106.9 IFU C. abortus,
it is possible that, depending on the exact titre of a particular batch
and whether or not the vaccines are administered in accordance
with manufacturers’ instructions, the dose may be low enough for
abortions to occur or high enough to effectively protect the flock.
Clearly, this would have important implications for consistency in
manufacturing and for those administering the vaccines to carefully
follow the manufacturers’ instructions. Therefore, taking all these
results and points into account we suggest that protection or other-
wiseof the1Bvaccine is unlikely tobedue to anychemically induced
SNPs and more likely dependent on the exact titre of a particular
batch of vaccine and the care taken in following manufacturers’
instruction during vaccine reconstitution and the inoculation of
the animals prior to pregnancy.
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Table 2
Additional SNPs present in C. abortus field strains isolated from the placentas of sheep that have aborted as a result of OEA.
Strain Genomic positiona CDS Predicted function SNP Amino acid change
10DC0084 75867 Cevac_0681 Phosphate permease A? T L? F
123293 Cevac_1301 Conserved hypothetical protein C? T A? V
288668 Cevac_2911 1,4-alpha-glucan branching enzyme C? T H
11_669_5380/2 185776 Intergenic G? A n/ab
681841 Cevac_6631 Conserved hypothetical protein T? G C? G
AB15 130861 Cevac_1381 Alcohol phosphatidyltransferase T? G S? A
a Genomic position on the 1B-Cevac genome (LN589721).
b n/a, not applicable.
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Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2018.05.
042.
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